October 10, 2024 | Thursday | News
New waters_connect MAP Sequence software accelerates RNA oligonucleotide mapping using semi-automated workflows
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LC-MS) analysis.
When used together in a workflow, these bioseparations tools help accelerate and improve the development of innovative large molecule RNA-based pharmaceuticals, such as CRISPR sgRNA and mRNA therapeutics.
Large molecule RNA (ribonucleic acid) therapeutics represent some of the most exciting and potentially life-saving developments in pharmaceuticals today. They include new and more effective vaccines for diseases like COVID-19, personalised cancer treatments, as well as emerging CRISPR RNA therapies that address challenging genetic conditions, such as sickle cell anaemia.
The Waters RNA analytical tools include:
Used together within a workflow, the tools generate an LC-MS fingerprint to confirm product identity, purity, and efficacy. The tools improve sequence coverage, LC-MS spectral data quality, and data interpretation. Supported by the compliance-ready waters_connect software platform, these tools help transition LC and LC-MS-based digestion analysis from discovery and development to release and at-line process analytical testing.
© Copyright 2024, MM Activ Sci-Tech Communications. All Rights Reserved.
Website Design & Developed By : SCI Knowledge Interlinks